Suppr超能文献

相似文献

2
[Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].
Mikrobiyol Bul. 2023 Apr;57(2):220-237. doi: 10.5578/mb.20239917.
4
In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Microb Drug Resist. 2016 Mar;22(2):172-8. doi: 10.1089/mdr.2015.0134. Epub 2015 Oct 15.
6
Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
PLoS One. 2018 Sep 17;13(9):e0203108. doi: 10.1371/journal.pone.0203108. eCollection 2018.
8
Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01503-18. Print 2018 Nov.
9
Epidemiology of Nontuberculous Mycobacteria in Tuberculosis suspects, Southwest of China, 2017-2022.
Front Cell Infect Microbiol. 2023 Oct 31;13:1282902. doi: 10.3389/fcimb.2023.1282902. eCollection 2023.
10
Antimicrobial Susceptibility Distributions of Clinical Isolates of Nontuberculous Mycobacteria in Israel.
Microb Drug Resist. 2023 Jul;29(7):302-308. doi: 10.1089/mdr.2023.0024. Epub 2023 May 23.

引用本文的文献

2
Drug susceptibility profiles of isolated in the state of São Paulo, 2008-2024.
J Med Microbiol. 2025 Apr;74(4). doi: 10.1099/jmm.0.002005.
4
The antimicrobial activity of linezolid against unconventional pathogens.
PeerJ. 2025 Feb 12;13:e18825. doi: 10.7717/peerj.18825. eCollection 2025.
5
6
Treatment outcomes in NTM-PD in a high TB burden context.
IJTLD Open. 2024 Dec 1;1(12):547-555. doi: 10.5588/ijtldopen.24.0413. eCollection 2024 Dec.
7
Durlobactam to boost the clinical utility of standard of care β-lactams against lung disease.
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0104624. doi: 10.1128/aac.01046-24. Epub 2024 Nov 20.
8
Toward better cures for lung disease.
Clin Microbiol Rev. 2024 Dec 10;37(4):e0008023. doi: 10.1128/cmr.00080-23. Epub 2024 Oct 3.
9
Imiquimod-Loaded Nanosystem for Treatment Human Papillomavirus-Induced Lesions.
Pharmaceutics. 2024 Jun 27;16(7):864. doi: 10.3390/pharmaceutics16070864.
10
Prevalence of in clinical and environmental isolates, a systematic review and meta-analysis.
Front Microbiol. 2024 Feb 19;15:1321273. doi: 10.3389/fmicb.2024.1321273. eCollection 2024.

本文引用的文献

2
Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study.
J Infect. 2021 Jul;83(1):46-53. doi: 10.1016/j.jinf.2021.05.019. Epub 2021 May 25.
3
Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey.
Infect Dis Poverty. 2021 Apr 29;10(1):59. doi: 10.1186/s40249-021-00844-1.
4
Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.
Med Res Rev. 2021 Jul;41(4):2350-2387. doi: 10.1002/med.21798. Epub 2021 Mar 1.
5
In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens.
J Antimicrob Chemother. 2021 Mar 12;76(4):973-978. doi: 10.1093/jac/dkaa520.
6
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.
7
Antimicrobial Susceptibility of Complex Clinical Isolates from a Chinese Tertiary Hospital.
Infect Drug Resist. 2020 Jun 26;13:2001-2010. doi: 10.2147/IDR.S252485. eCollection 2020.
9
Exosomes and Nanoengineering: A Match Made for Precision Therapeutics.
Adv Mater. 2020 May;32(18):e1904040. doi: 10.1002/adma.201904040. Epub 2019 Sep 18.
10
Non-tuberculous mycobacterial pulmonary disease.
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.00250-2019. Print 2019 Jul.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验